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Produced in Saccharomyces cerevisiae
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Process Development vs. Process Understanding
Process Development (PD) Objective:
– Design robust, controllable, and scalable processes to optimize productivity  and 












Process Understanding (PU) Objective:
– Identify critical inputs & outputs, and attempt to elucidate mechanistic 










physiology to protein 
expression kinetics 
PU Examples
S. cerevisiae: A Merck Vaccine Manufacturing Platform
Since 1980s to Present
•1986: FDA approved and licensed 
•Non-infectious subunit viral 
•1st vaccine to lead to 
link viral infection and 
carcinoma
•Virus-like particle 




•2006: FDA approved and licensed 
quadrivalent (HPV Types 6, 11, 16, 
18) vaccine.
Investigational   
S. aureus
Vaccine (SAV)
•Major surface transport iron 
protein from S. aureus expressed in          
S. cerevisiae
Physiological differences across all three programs were observed
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vaccine derived from hepatitis B 
surface antigen (HBsAg) expressed 
in S. cerevisiae.
•Unmet medical need:
•US 4-5000 deaths ann.
•Globally >1 million deaths ann.
• Fed-batch fermentation process 
with complex medium (YE, soy 
peptone, dextrose, amino acids)
•HPV major capsid protein L1 
expressed in S. cerevisiae which 
reassembles into virus-like particles 
following purification
•Unmet medical need:
•US 270,000 women died ann. 
(2002)
•Globally >0.5 million deaths ann.
•Leveraged RecombivaxHB process; 
chemically-defined fermentation 
medium
•2011: Phase II Clinical Candidate
•3 L, 15 L process development 
through process validation at 
manufacturing scale
•Leveraged RecombivaxHB and 
GARDASIL genetic engineering and 
process development
•SAV: Significantly reduced galactose metabolism during 
induction
Process Understanding in an Industrial Context
• Genome sequencing could reveal opportunity for genetic enhancement, 
but resource cost to implement would be high:
– Reproduce cGMP cell banks
– Potential for additional clinical studies
• Process understanding opportunity:
– Can we employ physiological characterization to better understand process
robustness? 
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– Can a process modification (e.g. medium, operating parameter) be employed to 
compensate for undesirable phenotype?
• Process understanding to be completed with line of sight to long-term 
understanding and manufacturing support – a change in paradigm: 
– Process development does not end with transfer to manufacturing 
– Life-cycle management requires that processes evolve with improved 
technologies, analytics, and increased demand
S. cerevisiae Basics: 
Central Carbon Metabolism
Complex glucose signaling regulatory network: 
• Crabtree effect (aerobic):
– Respiration:
• Low extracellular glucose
• Glycolytic flux with no pyruvate accumulation
• TCA cycle flux is high
– Fermentation:
• High extracellular glucose
• Glycolytic flux with high pyruvate accumulation 














• Overflow to ethanol, acetate, and glycerol
• Glucose genetic regulation:
– Derepression:
• Low extracellular glucose
• Signaling cascade to up-regulate large/diverse gene 
clusters (e.g., TCA cycle)
• Required for galactose metabolism and induction of 
protein expression.
– Repression:
• High extracellular glucose



















S. cerevisiae CEN.PK113-7D data shown. 
Otero, et al, 2009 PhD thesis. 









































Process Understanding Shake Flask Experiments:
Growth Evaluation on Various Carbon Sources
Error bars = 95% CI (n = 3)
• The lack of growth on ethanol 
in addition to galactose 
indicates that the expression 
strain has a respiratory 
deficiency
• Protein expression is not 
detrimental to growth in 
Initial Substrate Concentrations:







































comparison to the NORF strain 
(data not shown)
• No protein production without 
galactose – no leaky expression
• Galactose uptake must be 
occurring in order to promote 
transcription of the antigen 
gene (data not shown) 
Expression Strain Lineage
These strains were selected as 
comparisons to the expression strain 
for growth on glucose or galactose
Strain A Strain B
Strain A’
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Clones at each step were 
selected by maximum 
growth rate on glucose
Strain AB
























Strain A Strain B
Strain A’







































































































































































Chemostat: A Process Understanding Tool
• Continuous addition of medium and removal of culture allows the 
growth rate to be controlled and maintained at steady state
• Dilution rate = 0.2 h-1
– μmax of strain was determined to be 0.29 h
-1 during batch culture
• Can determine the impact of galactose addition in the presence of a 
consumable carbon source (glucose)
• Transcriptome and exo-metabolome samples taken during glucose 
steady state and galactose steady state allow us to look for differences 








(1x media + 
50 g/L glucose)





• Cell-specific growth rate was slower than glucose-limited feed rate resulting in washout
• Confirms respiratory deficiency of the strain, since the fermentative growth rate, which was 
demonstrated to be significantly higher than 0.2 h-1, could not be maintained in a respiratory regime
• Glucose feed rate during the fed-batch process is equivalent to a cell-specific growth rate of 0.13 h-1
(cells are able to respire, RQ = 1) 
• Try repeating the chemostat experiment with D = 0.1 h-1!
Batch Phase Reaching Steady State Glucose Steady State Galactose
Co-Feed
Post-feed
Chemostat CER and Biomass Profiles (D = 0.1 h-1)
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• Affymetrix Yeast 2.0
• Transcriptome samples 
grouped based on different 
phases of the process:
– Glucose steady state
– Galactose co-feed
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– Final sample (post-feed)




Galactose Co-Feed vs. Glucose Steady State
• Contrary to previous hypothesis, the presence of galactose does not 
cause any abnormal gene expression response by the strain
• Response was typical for a galactose-consuming strain
GO Process, Galactose co-feed (last timepoint) vs. Glucose
galactose metabolic process
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1.00E-04 1.00E-03 1.00E-02 1.00E-01 1.00E+00
DNA-dependent DNA replication
galactose catabolic process via UDP-galactose
heteroduplex formation
cellular response to stimulus
recombinational repair
carbohydrate metabolic process
cellular response to stress
P-value
Metabolic Pathways: 











Quantification of 63 
metabolites and elements for 
chemostat experiment samples 
and manufacturing samples     
(3 lots at mfg. scale)
There is a clear grouping by 
process step in the 
16Exo-Metabolome analysis courtesy of TNO Innovation for Life
manufacturing samples with 
respect to the principal 
components.
This grouping could not be 
reproduced  in the chemostat, 









• Confirmed respiratory deficiency of the 
expression strain
• Respiratory capacity was reduced during 
expression strain development
• Transcriptome analysis revealed no dysfunction in 
transcription of any of the major galactose 
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metabolic pathway genes
• Exo-metabolome analysis demonstrated little 
variation in any of the chemostat samples when 
compared to the manufacturing process
Impact: Why should process development 
invest in understanding?
• Defining experimental space:
– Where not to invest resources is just as valuable as determining where to 
invest resources.
– Hypothesis: Altered physiology observed was due to addition of galactose 
and subsequent metabolism
– Conclusion: False. More significant strain differences observed.
• Regulatory agency expectations are increasing:
– Life-cycle management requires that we continuously invest in our 
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franchises. It’s not about what the FDA requires today, but what questions 
will it ask 10-20 years from now?
• Invest in expression systems engineering:
– Process development groups may have ‘preferred’ cell substrates from 
historical programs, but assumptions should be challenged with newly 
available tools (deep sequencing, bioinformatics, phenotype/genotype 
relationships).
– Example: RecombivaxHB (1986), Gardasil (2006), Investigational SAV (2011)
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• Non-infectious subunit viral vaccine derived from hepatitis B 
surface antigen.
– Viral gene encoding HBsAg  (adw serotype) cloned into S. 
cerevisiae
– Complex fermentation medium (yeast extract, soy peptone, 
glucose, amino acids, salts).
– Non-secreted product  requires cell disruption
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• S. cerevisiae Advantages
– Easy regulatory approval due to GRAS status
– Laboratory process development easily scaled up to >1000L 
fermentations
– Process developed during 1980s
• Successful even without today’s advances  robust!
All information presented is publicly available: 
www.merck.com/product/usa/pi_circulars/r/recombivax_hb/recombivax_pi.pdf 
Gardasil™
• Human Papillomavirus (HPV)
– Many viral types leading to diverse infection states
• HPV Types 6/11  genital warts
• HPV Types 16/18 (31/45/52/58/33)  cervical cancer
• Non-infectious major surface protein (L1 protein, 55-57 kDa) of HPV viral capsid encoded in S. cerevisiae
– Intracellular expression in S. cerevisiae
– L1 protein of HPV Types 6/11/16/18  independent fermentations lead to 
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formation of virus-like particle (VLP)
– Different VLPs then mixed to form Gardasil™
– Clinical efficacy thus far – 99.99%
• Gardasil™ Quadrivalent approved in US and EU
– Recommended by USA FDA to be reviewed as a mandatory vaccine
– Analysts expect sales >$ 1 billion USD
• Development on 2nd generation HPV vaccines and process actively underway
All information presented is publicly available: www.gardasil.com
S. cerevisiae Basics: 
Central Carbon Metabolism
Complex glucose signaling regulatory network: 
• Crabtree effect (aerobic):
– Respiration:
• Low extracellular glucose
• Glycolytic flux with no pyruvate accumulation
• TCA cycle flux is high
– Fermentation:
• High extracellular glucose
• Glycolytic flux with high pyruvate accumulation 














• Overflow to ethanol, acetate, and glycerol
• Glucose genetic regulation:
– Derepression:
• Low extracellular glucose
• Signaling cascade to up-regulate large/diverse gene 
clusters (e.g., TCA cycle)
• Required for galactose metabolism and induction of 
protein expression.
– Repression:
• High extracellular glucose



















S. cerevisiae CEN.PK113-7D data shown. 
Otero, et al, 2009 PhD thesis. 
Critical Control Parameter: Glucose Feed Rate
• Glucose Feed Rate Factor:
– GARDASIL™ Process Development: The 
specific growth rate was determined 
based on oxygen uptake rate. This 
process used same feed rate profile – no 
consideration for strain difference.
– Process Understanding: Determined 
specific growth rate based on direct 
measurement of biomass – OD600 and 
dry cell weight.



















Type 6 Flowrate (1X)
Type 6 Flowrate (1.2X)
Type 6 Flowrate (0.8X)
1x Flow rate
1.2x Flo  rate

















Changes in the feed rate factor (0.8x, 1.2x) do not change the exponential rate of 
glucose feed  it is the exponential rate of feed that correlates to physiological growth 
rate
So why does the manufacturing process work?
• The manufacturing process utilizes a glucose limited exponential feed
– The feed rate profile was determined based on GARDASIL™ Process Development 
with no consideration for strain difference
– Glucose feed rate is equivalent to a cell specific growth rate of 0.13 h-1

























Explains why respiratory 
deficiency observed could not be 
reconciled with fed-batch profile

















































uridinephosphoglucose pyrophosphorylase: UGP1                        










UDP-glucose-4-epimerase      
GAL10
galactose-1-phosphate uridylyltransferase                        
GAL7
glycolysis
S. cerevisiae Transcriptional Profiling
• Well-annotated genome
– First eukaryotic genome fully sequenced (Goffeau, et al. 
Science. 1996)
– Saccharomyces Genome Database (www.yeastgenome.org)
• Collects information and maintains a database of the molecular biology 
of S. cerevisiae




– Yeast Genome 2.0 Array – contains probe sets to detect 
transcripts from S. cerevisiae and S. pombe
– Used in most major yeast laboratories
• Molecular Profiling
– Merck acquired Rosetta in 2001
– Leaders in DNA array technology
Transcriptional Comparison of Galactose Conditions 









































• There does not appear to be a “dose-response” effect in terms of transcriptional levels as 
galactose concentration increases
• All galactose co-feed conditions can be combined into one galactose group
– Increases statistical power of comparison to glucose
Adding galactose to the medium when there is a consumable carbon source 
present produces the expected transcriptional response. Galactose does not 














Boron ICP-AES / ICP-MS
Calcium ICP-AES / ICP-MS
Cobalt ICP-AES / ICP-MS
Copper ICP-AES / ICP-MS
Iron ICP-AES / ICP-MS
Magnesium ICP-AES / ICP-MS
Manganese ICP-AES / ICP-MS
Molybdenum ICP-AES / ICP-MS
Nickel ICP-AES / ICP-MS









Nicotinic acid (Niacin) OS-GC-MS
Oleic acid OS-GC-MS
Oxalic acid OS-GC-MS












Sodium ICP-AES / ICP-MS





















+ / NH3 Colorimetric (2)1. The AminoTac can only detect cystine, and not cysteine
2. Requires the colorimetric analysis of NH4
+; based on the acid constant (pKa) of 
the NH4
+/NH3 couple the pH, the ratio between NH4+/NH3 can be calculated
Biological Interpretation of Glycerol Yields
• In S. cerevisiae, glycerol is involved in
– Balancing redox potential
– Osmotic stress response
• Under anaerobic conditions, glycerol 
is produced to regenerate NAD+ from 
excess NADH accumulated during 
biomass production1








dehydrodgenases or the Glycerol-3-
phosphate shuttle can be used to 
oxidize redox equivalents1
• High glycerol yields observed with SAV 
expression strain may be linked to the 












1. J.-M.A. Geertman et al. Metabolic Engineering 8 (2006) 532-542



























































































































































• Data sets composed of n variables are converted into an n-dimensional space
– The human mind can’t interpret data sets visualized in multi-hundred or multi-thousand 
dimensional spaces
– Therefore, it is necessary to project an n-dimensional space into a 2- or 3-dimensional space
• PCA concentrates strongly correlating variables, i.e. variables that vary in a similar 
way in all data sets, into a new variable
• This new variable, the principal component (PC) is a linear combination of the original 
variables
• PCA aims at establishing relationships between the m rows (biological samples) and n
columns (variables, e.g. gene expression levels or metabolite concentrations) of a 
matrix (dimension m x n)
• A plot can be drawn of two PC’s which allows the similarity of samples to be 
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visualized






























Strain A Strain B
Strain A’


























































































































































































































































Process Understanding Shake Flask Experiments:
Growth Evaluation on Various Carbon Sources
Error bars = 95% CI (n=3)
Initial Substrate Concentrations:





























Leaky expression was not found in 
the absence of galactose; galactose 
uptake must be occurring in order 
to promote transcription of the 
antigen gene (data not shown).
The lack of growth on ethanol as a 
sole carbon source supports the 
hypothesis that the expression 
strain has a general respiratory 
deficiency, not just a galactose 
pathway dysfunction
